Curi Bio key facts
as of Oct 2026- Developer of a human stem cell-based platform designed to facilitate the discovery of medicines by integrating human cells, systems, and data.
- Curi Bio is valued at approximately $62.0M as of Oct 2026 (last reported valuation).
- It has raised $20.1M; the latest was Later Stage VC ($10.0M) in Dec 2025.
- Notable investors include National Institutes of Health, UTC Investment, Double Capital, DS Asset Management, Dream CIS — 13 tracked in total.
- Status: Privately Held (backing).
Curi Bio's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Curi Bio: the Monday email on marks, rounds and moves
Curi Bio funding rounds
No funding rounds for Curi Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Curi Bio
13+Curi Bio valuation
Curi Bio's last reported valuation was $62 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Curi Bio investors
13 investors are on record for Curi Bio, including National Institutes of Health, UTC Investment, Double Capital and DS Asset Management.
About Curi Bio
Developer of a human stem cell-based platform designed to facilitate the discovery of medicines by integrating human cells, systems, and data. The company's technology provides a suite of products for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research, which promotes in vivo maturation and alignment of cell types, enabling drug developers to accurately test the safety and efficacy of new drugs.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2015
- Employees
- 47
- Website
- curibio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.